Malignant Renal Pelvis Neoplasm

subtype

Identifier: CI-CAN-00005928
Entity page: /cancer/malignant-renal-pelvis-neoplasm ↗
Edges: 67

Neighbours: 15 drugs10 trials
Drawn: 25 of 25 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Malignant Renal Pelvis Neoplasm investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 27show all (up to 200)
→ investigated in trials for	Nivolumabmonoclonal antibody 6 trials (6 active) · roll-up of the cancer and its descendants	—	—	Malignant Renal Pelvis Neoplasm	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Pembrolizumab

Malignant Renal Pelvis Neoplasm studied in …STUDIED_INderived10 of 40show all (up to 200)
→ studied in	NCT05874921recruiting uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto · condition mapped ALIAS · 40 trials mapped (20 active)	—	—	Renal Pelvis Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05987241Phase 2/Phase 3 · recruiting Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study · condition mapped ONTOLOGY_EXACT · 40 trials mapped (20 active)	—	—	Muscle Invasive Renal Pelvis Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04963153Phase 1 · active not recruiting Testing Combination Erdafitinib and Enfortumab Vedotin in Metastatic Bladder Cancer After Treatment With Chemotherapy and Immunotherapy · condition mapped CURATED_BROADER · 40 trials mapped (20 active)	—	—	Renal Pelvis Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07667335Phase 1/Phase 2 · recruiting Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer · condition mapped CURATED_BROADER · 40 trials mapped (20 active)	—	—	Renal Pelvis Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT04940299Phase 2 · active not recruiting Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma · condition mapped CURATED_BROADER · 40 trials mapped (20 active)	—	—	Renal Pelvis Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02812420early Phase 1 · active not recruiting Durvalumab and Tremelimumab in Treating Patients With Muscle-Invasive, High-Risk Urothelial Cancer That Cannot Be Treated With Cisplatin-Based Therapy Before Surgery · condition mapped ALIAS · 40 trials mapped (20 active)	—	—	Invasive Renal Pelvis Sarcomatoid Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT05059444recruiting ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation · condition mapped ONTOLOGY_EXACT · 40 trials mapped (20 active)	—	—	Renal Pelvis Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02496208Phase 1 · active not recruiting Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors · condition mapped ONTOLOGY_EXACT · 40 trials mapped (20 active)	—	—	Renal Pelvis Urothelial Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06465069Phase 1 · recruiting A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors · condition mapped ALIAS · 40 trials mapped (20 active)	—	—	Renal Pelvis Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT06661720Phase 3 · recruiting Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer · condition mapped CURATED_BROADER · 40 trials mapped (20 active)	—	—	Renal Pelvis Carcinoma	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Strongest chains